Insomnia evaluation and treatment
Lying awake or waking too early can affect concentration and make bedtime feel frustrating. An Ondoc licensed clinician can assess sleep patterns and discuss CBT-I and medication options; Insurance or $50 self-pay.
What your visit can cover
- Sleep schedule and contributing medicines, mood symptoms, or apnea risks reviewed
- CBT-I referral or behavioral plan focused on persistent insomnia
- Discuss medication benefits, risks and contributing conditions
When to be seen in person
Loud snoring, witnessed breathing pauses, or major daytime sleepiness warrants assessment for sleep apnea. Seek urgent mental health care for little sleep with unusually high energy or unsafe behavior, and do not drive while drowsy.
About Insomnia
Insomnia means difficulty falling asleep, staying asleep or waking too early despite enough opportunity to sleep, with daytime effects. Chronic insomnia usually occurs at least three nights a week for at least three months. Cognitive behavioral therapy for insomnia (CBT-I) is the recommended first treatment for persistent insomnia; it addresses sleep habits and the worry and behaviors that keep sleep problems going. Snoring with breathing pauses may indicate sleep apnea, a different problem. Ondoc can review sleep patterns, medicines and contributing conditions, discuss a treatment plan and refer for CBT-I or sleep assessment.
AASM: pharmacologic treatment of chronic insomnia
Sleep medicines and supplements to discuss
CBT-I is an established first treatment for chronic insomnia. Medicines differ in whether they help sleep onset, staying asleep or sleep disturbances linked to another condition. Your provider considers these differences, interactions and next-day effects. Strengths are catalog entries, not dosing instructions.
- Melatonin3 mg · 5 mg
A supplement that may help some sleep-timing problems. Evidence has not established it as an effective treatment for chronic insomnia.
- Trazodone (Desyrel)50 mg · 100 mg
An antidepressant sometimes used off-label for sleep disturbances, including when depression is present. It is not FDA-approved for insomnia; AASM does not recommend it for routine chronic-insomnia treatment. Dizziness and next-day sedation can occur.
- Hydroxyzine25 mg · 50 mg
A sedating antihistamine sometimes used off-label for sleep disturbance associated with anxiety or itching. It is not FDA-approved for insomnia; next-day sedation and heart-rhythm risks require consideration.
Additional medication information
Educational options, not an offer of a prescription from every provider. No dose or ordering instruction is provided.
- Eszopiclone (Lunesta)
- FDA-approved for insomnia and can help falling asleep and staying asleep. It is a controlled medicine; complex sleep behaviors and next-day impairment are important risks.
- Doxepin for insomnia
- The low-dose insomnia formulation is FDA-approved for difficulty staying asleep. Higher-dose antidepressant formulations have different indications.
- Ramelteon (Rozerem)
- FDA-approved for insomnia involving difficulty falling asleep. It acts on melatonin receptors and is not a controlled substance.
- Mirtazapine (Remeron)
- FDA-approved for major depression, not insomnia. It may help sleep when depression is present; sleep use is off-label, and increased appetite, weight gain and sedation can occur.
- Quetiapine (Seroquel)
- Used for schizophrenia and bipolar disorder; extended-release quetiapine also has an adjunctive depression indication. Sleep use is off-label, not an established treatment for uncomplicated chronic insomnia. Sedation may help sleep in some patients treated for these conditions, but metabolic and movement effects matter.
- Other FDA-approved insomnia options
- Zolpidem and zaleplon are controlled sleep medicines; suvorexant, lemborexant and daridorexant are controlled orexin-receptor antagonists. Their sleep indications and risks differ, and your provider decides whether any is appropriate.